Browsing eNauka
Browsing by Author Boehnke, Axel
Showing results 1 to 6 of 6
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2017 | Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial | Davies, Andrew; Merli, Francesco; Mihaljevic, Biljana S  ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;
Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;
| Article | 21a+M21a+ |
| 2013 | Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follic | Davies, AJ; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, M; MacDonald, D | Conference Paper | Mp. category will be shown later |
| 2012 | Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follic | Davies, Andrew J; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, Martin; Macdonald, David | Conference Paper | Mp. category will be shown later |
| 2014 | Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study | Davies, Andrew; Merli, Francesco; Mihaljević, Biljana ; Siritanaratkul, Noppadol; Solal-Céligny, Phillippe; Barrett, Martin; Berge, Claude; Bittner, Beate; Boehnke, Axel; McIntyre, Christine;
MacDonald, David;
| Article | 21a+M21a+ |
| 2014 | Subcutaneous Rituximab and Chemotherapy Achieves Similar Overall Response Rates to Intravenous Rituximab in First-Line Follicular Lymphoma: Efficacy and Safety Results of the Phase Iii Sabrina Study | Davies, A; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Cambon, N; Macgregor, L; Brewster, M;
Barrett, M; MacDonald, D;
| Conference Paper | Mp. category will be shown later |
| 2013 | Subcutaneous Rituximab and Chemotherapy Achieves Similar Trough Levels, Safety, and Response as Intravenous Rituximab in First-Line Follicular Lymphoma: Stage 1 Results of the Phase 3 Sabrina Study | Davies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, Martin; Macdonald, David | Conference Paper | Mp. category will be shown later |